食管癌新辅助免疫治疗研究进展  

Research progress on neoadjuvant immunotherapy for esophageal cancer

作　　者：易亮 黄惠 袁智勇 章文成 Yi Liang;Huang Hui;Yuan Zhiyong;Zhang Wencheng(Department of Radiation Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China)

机构地区：[1]天津医科大学肿瘤医院放疗科,国家恶性肿瘤临床医学研究中心,天津市肿瘤防治重点实验室,天津市恶性肿瘤临床医学研究中心,天津300060

出　　处：《中华放射肿瘤学杂志》2023年第7期638-643,共6页Chinese Journal of Radiation Oncology

基　　金：国家自然科学基金(81872462,82272733);天津市医学重点学科(专科)建设项目(TJYXZDXK-009A)。

摘　　要：新辅助治疗尤其是新辅助放化疗已成为局部晚期可切除食管癌的术前标准治疗,但患者术后仍有较高的复发率和远处转移率。近年来,程序性死亡蛋白-1(PD-1)/程序性死亡蛋白配体-1(PD-L1)免疫检查点抑制剂在免疫治疗方面被广泛应用于肿瘤治疗,在新辅助化疗/新辅助放化疗基础上联合PD-1/PD-L1免疫检查点抑制剂能否进一步提高疗效、增加手术完全切除率以及安全性等方面是目前研究的热点。本文就食管癌新辅助免疫联合化疗/放化疗做一综述。Neoadjuvant therapy,especially neoadjuvant chemoradiotherapy,has become the standard preoperative treatment for locally advanced resectable esophageal cancer,whereas the recurrence and distant metastasis rates after surgery remain high.In recent years,programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1)immune checkpoint inhibitors have been widely adopted in immunotherapy for cancer.Whether PD-1/PD-L1 immune checkpoint inhibitors combined with neoadjuvant chemotherapy/neoadjuvant chemoradiotherapy could further improve clinical efficacy,increase the complete surgical resection rate and safety are current research hotspots.In this article,neoadjuvant immunotherapy combined with chemotherapy/radiochemotherapy for esophageal cancer was reviewed.

关 键 词：食管肿瘤 新辅助疗法 肿瘤/免疫疗法 研究进展 

分 类 号：R735.1[医药卫生—肿瘤]